Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat, today announced the appointment of Lara S. Sullivan, M.D. to its board of directors.
{iframe}https://investors.rexahn.com/press-releases/detail/294/rexahn-pharmaceuticals-appoints-lara-s-sullivan-to-its{/iframe}